SG Americas Securities LLC Increases Stake in Establishment Labs Holdings Inc. $ESTA

SG Americas Securities LLC boosted its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 134.3% during the first quarter, HoldingsChannel reports. The fund owned 37,928 shares of the company’s stock after buying an additional 21,742 shares during the quarter. SG Americas Securities LLC’s holdings in Establishment Labs were worth $2,154,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its position in Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after purchasing an additional 438,206 shares during the period. Viking Global Investors LP purchased a new stake in shares of Establishment Labs during the 2nd quarter valued at approximately $14,669,000. Bamco Inc. NY boosted its holdings in Establishment Labs by 30.2% in the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after buying an additional 274,287 shares during the period. Soleus Capital Management L.P. purchased a new position in Establishment Labs in the 2nd quarter valued at approximately $9,050,000. Finally, Summit Partners Public Asset Management LLC grew its stake in Establishment Labs by 87.1% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock valued at $17,632,000 after buying an additional 200,255 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ESTA shares. BTIG Research raised their price target on Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. TD Cowen reiterated a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $87.14.

Insider Transactions at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the sale, the director directly owned 927,504 shares in the company, valued at $69,952,351.68. This represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 292,500 shares of company stock worth $20,591,021 in the last ninety days. Corporate insiders own 9.99% of the company’s stock.

Establishment Labs Trading Up 4.0%

NASDAQ ESTA opened at $89.23 on Thursday. The stock’s 50-day simple moving average is $74.89 and its two-hundred day simple moving average is $70.67. Establishment Labs Holdings Inc. has a twelve month low of $33.35 and a twelve month high of $90.50. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The company has a market capitalization of $2.63 billion, a price-to-earnings ratio of -59.89 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Establishment Labs’s revenue for the quarter was up 44.7% compared to the same quarter last year. Research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.